These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

330 related items for PubMed ID: 32147246

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Pitolisant, a wake-promoting agent devoid of psychostimulant properties: Preclinical comparison with amphetamine, modafinil, and solriamfetol.
    Krief S, Berrebi-Bertrand I, Nagmar I, Giret M, Belliard S, Perrin D, Uguen M, Robert P, Lecomte JM, Schwartz JC, Finance O, Ligneau X.
    Pharmacol Res Perspect; 2021 Oct; 9(5):e00855. PubMed ID: 34423920
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Comparative Efficacy and Safety of Wakefulness-Promoting Agents for Excessive Daytime Sleepiness in Patients With Obstructive Sleep Apnea : A Systematic Review and Network Meta-analysis.
    Pitre T, Mah J, Roberts S, Desai K, Gu Y, Ryan C, Busse JW, Zeraatkar D.
    Ann Intern Med; 2023 May; 176(5):676-684. PubMed ID: 37155992
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Solriamfetol for the treatment of daytime sleepiness in obstructive sleep apnea.
    Abad VC, Guilleminault C.
    Expert Rev Respir Med; 2018 Dec; 12(12):1007-1019. PubMed ID: 30365900
    [Abstract] [Full Text] [Related]

  • 9. Pitolisant for Residual Excessive Daytime Sleepiness in OSA Patients Adhering to CPAP: A Randomized Trial.
    Pépin JL, Georgiev O, Tiholov R, Attali V, Verbraecken J, Buyse B, Partinen M, Fietze I, Belev G, Dokic D, Tamisier R, Lévy P, Lecomte I, Lecomte JM, Schwartz JC, Dauvilliers Y, HAROSA I Study Group.
    Chest; 2021 Apr; 159(4):1598-1609. PubMed ID: 33121980
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Solriamfetol Titration & AdministRaTion (START) in Patients With Narcolepsy.
    Thorpy MJ, Hyman D, Parks GS, Chen A, Foley C, Baldys B, Ito D, Singh H.
    Clin Ther; 2022 Oct; 44(10):1356-1369. PubMed ID: 36171171
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and safety of solriamfetol for excessive daytime sleepiness in narcolepsy and obstructive sleep apnea: a systematic review and meta-analysis of clinical trials.
    Subedi R, Singh R, Thakur RK, K C B, Jha D, Ray BK.
    Sleep Med; 2020 Nov; 75():510-521. PubMed ID: 33032062
    [Abstract] [Full Text] [Related]

  • 14. Solriamfetol Titration and AdministRaTion (START) in Patients with Obstructive Sleep Apnea: A Retrospective Chart Review and Hypothetical Patient Scenario.
    Singh H, Hyman D, Parks GS, Chen A, Foley C, Baldys B, Ito D, Thorpy MJ.
    Adv Ther; 2022 Sep; 39(9):4359-4373. PubMed ID: 35927541
    [Abstract] [Full Text] [Related]

  • 15. Profile of Solriamfetol in the Management of Excessive Daytime Sleepiness Associated with Narcolepsy or Obstructive Sleep Apnea: Focus on Patient Selection and Perspectives.
    Abad VC.
    Nat Sci Sleep; 2021 Sep; 13():75-91. PubMed ID: 33531850
    [Abstract] [Full Text] [Related]

  • 16. Incidence and duration of common early-onset adverse events in randomized controlled trials of solriamfetol for treatment of excessive daytime sleepiness in obstructive sleep apnea and narcolepsy.
    Rosenberg R, Thorpy MJ, Dauvilliers Y, Schweitzer PK, Zammit G, Gotfried M, Bujanover S, Scheckner B, Malhotra A.
    J Clin Sleep Med; 2022 Jan 01; 18(1):235-244. PubMed ID: 34283019
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Indirect treatment comparison of solriamfetol, modafinil, and armodafinil for excessive daytime sleepiness in obstructive sleep apnea.
    Ronnebaum S, Bron M, Patel D, Menno D, Bujanover S, Kratochvil D, Lucas E, Stepnowsky C.
    J Clin Sleep Med; 2021 Dec 01; 17(12):2543-2555. PubMed ID: 34402784
    [Abstract] [Full Text] [Related]

  • 19. Long-term effects of solriamfetol on quality of life and work productivity in participants with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea.
    Weaver TE, Pepin JL, Schwab R, Shapiro C, Hedner J, Ahmed M, Foldvary-Schaefer N, Strollo PJ, Mayer G, Sarmiento K, Baladi M, Bron M, Chandler P, Lee L, Malhotra A.
    J Clin Sleep Med; 2021 Oct 01; 17(10):1995-2007. PubMed ID: 34606437
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.